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ABSTRACT 
Objective: There is a decreased breast cancer risk in SLE versus the general population. We assessed a 
large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk.     
Methods: We performed case-cohort analyses within a multi-centre international SLE sample. We 
calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, 
reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA 
positivity, cumulative disease activity, and drugs, adjusted for SLE duration.  
Results: There were 86 SLE breast cancers and 4,498 female SLE cancer-free controls. Patients were 
followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and 
older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity and 
most drug exposures over time. In univariate and multivariate models, the principal factor associated 
with breast cancers was older age at cohort entry. 
Conclusions: There was little evidence that breast cancer risk in this SLE sample was strongly driven by 
any of the clinical factors that we studied. Further search for factors that determine the lower risk of 
breast cancer in SLE may be warranted. 
Abstract word count: 190 
Manuscript word count: 2,705 
Key words: Breast cancer, systemic lupus erythematosus 
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Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by widespread 
inflammation leading to a multitude of manifestations in skin, joints, kidneys, and other organs. In SLE, 
there appears to be about an overall 15% increase in cancer but a decrease in certain cancers.1 [1] 
Specifically, the standardized incidence ratio (or relative rate) for breast cancer in SLE has been 
estimated in a meta-analysis to be 0.76 (95% confidence interval, CI 0.69-0.85) when compared to age 
and sex matched general population controls.2[2] Many theories have arisen in an attempt to explain this 
phenomenon, such as hypotheses that breast cancer risk in SLE may be reduced by drug exposures (non-
steroidal anti-inflammatory drugs, NSAIDs, anti-malarial drugs, etc) or autoantibody profiles, but no 
data have evaluated these hypotheses. 
Our primary objective was thus to assess breast cancer risk in females with SLE, comparing 
patients in terms of demographic and clinical factors. 
 
Methods:  
We used data from a very large multi-site international SLE cohort (30 centres, 16,409 patients), 
with the participation of collaborating centres from two research networks, the Systemic Lupus 
International Collaborating Clinics (SLICC) and the Canadian Network for Improved Outcomes in 
Systemic Lupus, as well as other collaborators3.[3] The patients, who either fulfill the 1997 American 
College of Rheumatology (ACR) classification criteria for SLE4[4] or have a clinical diagnosis of SLE 
made by a rheumatologist, are enrolled in clinical cohort registries and followed by specialists.  
The case-cohort design is a well-described variant of the standard case-control study, which 
optimizes flexibility and efficiency.  In this design, a random subset is chosen from the baseline patients 
(who are all free of the event of interest) and that subset is the source of controls over time. At each 
cancer ‘event’ that occurs over time, the case is compared to the cancer-free controls remaining in that 
subset sample, on the exposures and variables of interest. The statistical analysis is a modified hazard 
regression. 5[5] 
Although all centres who participated in our very large cohort study collect data on 
demographics, 18 centres provided the data required for a case-cohort analysis. The data was not 
uniformly available on all patients across the 18 cohorts; in some cases, the centres had to perform chart 
review to obtain the necessary variables. This made the case-cohort approach more feasible than a 
simple cohort analysis.  Thus, the data presented in this analysis are from these centres: Halifax, 
Montreal, Toronto, Winnipeg, (all in Canada), Baltimore, Chicago, San Francisco Bay Area, Albert 
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Einstein, New York City – State University of New York, South Carolina, (all in the United States), 
Copenhagen (Denmark), London and Birmingham (England), Bizkaia (Spain), Seoul (South Korea), 
Hannover (Germany), Lund (Sweden), and Mexico City (Mexico).  
We studied only breast cancer cases that had occurred after entry into the lupus cohort at each 
centre and up to the time of cohort exit (defined by death or date of last visit). The index time for each 
risk (case-control) set was the date of the case’s breast cancer occurrence, with time since SLE diagnosis 
as the time axis. The controls for each risk set, for each breast cancer case, represented all the subcohort 
members who remained cancer-free up to that index time. Subjects who developed a cancer other than 
breast cancer were right-censored. 
We used the modified Cox proportional hazards regression case-cohort analyses to calculate the 
hazard ratio (HR) for breast cancer risk in female SLE patients. We included in our model a time-
dependent measure, the mean adjusted SLE disease activity, based on SLE Disease Activity Index 
(SLEDAI-2K) scores over time6.[6]  We were also interested specifically in autoantibody profiles, so for 
our analyses we removed the item for anti-dsDNA from the SLEDAI scores and constructed a separate 
variable for this. To produce ‘mean adjusted SLEDAI-2K’ scores over time we used the previously 
published approach7[7] of calculating areas under the curve for SLEDAI-2K values from time zero to 
the event time of each risk set. The area under the curve is then divided by the time over which activity 
has been measured (this time is the same for all members of a risk set) and this produces a mean 
adjusted SLEDAI-2K, which has the same units as the original SLEDAI-2K measure. The mean 
adjusted SLEDAI-2K scores for each member of each risk set was categorized into quartiles, and in our 
primary analyses, our variable captured the effect of being in the highest quartile of mean adjusted 
SLEDAI-2K (versus lower disease activity).  At one centre (San Francisco), disease activity was 
captured only with self-report items of disease activity, as opposed to the standard physician-scored 
SLEDAI-2K, using a measure validated against the SLEDAI.8[8] We performed sensitivity analyses with 
and without this centre and results were essentially unchanged, hence the primary results reported in this 
paper included all centres.  
As mentioned, we also evaluated anti-dsDNA positivity, using a weighted average of the number 
of times patients were anti-dsDNA antibody positive over time. The dsDNA antibody test information 
that we relied on was based on the ACR classification criterion for dsDNA antibody positivity at cohort 
enrolment, as well as the SLEDAI-2K disease activity item for this test. The dsDNA antibody testing 
was done locally at each centre with variable assays. 
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The data on demographics (age at cohort entry, as a continuous time-dependent variable, and 
race/ethnicity), disease activity over time, and all medications of interest, were prospectively recorded in 
the clinic database and/or medical records at each centre. Medications were included as time-dependent 
variables for ever-never use, for all the medications listed in Table 2. We included cumulative exposures 
for systemic steroids, azathioprine, cyclophosphamide, and anti-malarial agents, in our full multivariate 
model. These variables, calculated from the most detailed records available, used cut-offs as previously 
described9, We also included variables for menopausal status, family history of breast cancer, and 
number of pregnancies As time zero for the observation interval was SLE diagnosis, our analyses also 
adjusted for SLE duration, and we adjusted for calendar year. We included one set of analyses where we 
stratified results by centre in order to account for the possibility of differences across centres. Both the 
stratified and non-stratified multivariable models were adjusted for all demographic and clinical 
variables in the model.      
 
Results:  
We analyzed 86 SLE breast cancers cases and 4,498 female SLE controls. Patients had been 
followed an average of 7.6 (standard deviation 6.9) years.  In the descriptive analyses, compared to 
controls, SLE breast cancer cases tended to be older at cohort entry (Table 1) and white (possibly 
reflecting racial/ethnic variations in breast cancer risk in the general population)10.[10] Breast cancer cases 
were similar to controls regarding baseline disease activity. A similar proportion of cases and cancer-
free controls were anti-dsDNA positive at cohort entry, and through the observation interval. 
In univariate and multivariate models (Table 2), the principal demographic factor associated with 
breast cancers was older age at cohort entry. In univariate analyses only, white race/ethnicity, hormone 
replacement therapy, menopausal status, and family history of breast cancer were positively associated 
with breast cancer; these associations were imprecise in the multivariate analyses.  For most of the drug 
exposures, the HR confidence intervals were wide.  A negative correlation between cumulative 
azathioprine and breast cancer was suggested in univariate analyses but in the multivariate analyses the 
HR was close to the null value. We could not detect a clear association of breast cancer risk with SLE 
disease activity (excluding dsDNA positivity) or anti-dsDNA positivity over time.   
 
DISCUSSION: 
As mentioned in the introduction, previous data clearly point towards a decreased risk of breast 
cancer in SLE2,3, 11.[2,3,11] Many theories have arisen in an attempt to explain this phenomenon, such as 
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hypotheses that breast cancer risk in SLE may be reduced by drug exposures (non-steroidal anti-
inflammatory drugs, NSAIDs, anti-malarial drugs, etc) or autoantibody profiles, but our study is the first 
to explore these hypotheses.  
In fact, our novel study is one of only a handful of investigations focussing on breast cancer risk 
in SLE. One previous study relied on administrative data from the United States, which studied only 
elderly patients without clinically confirming their diagnosis of SLE12. That study showed a decreased 
risk for estrogen receptor-negative breast cancer, but was unable to examine clinical factors such as 
antibody positivity or drug use.  
Of particular interest are autoantibodies targeting DNA, particularly since (in animal models and 
cell cultures) some of these antibodies may penetrate cells and interfere with DNA repair, and so 
potentially be lethal to cancer cells and hence protect against breast cancer.13[13] This may be most 
important for BRCA2-deficient breast cancers; unfortunately we did not have enough detailed 
information on pathology (or sufficient power) to study this subset of malignancies, which do not 
account for the majority of cancers in the general population (or SLE)14.[14] 
 Despite strengths, there are several potential limitations to our study. The mean adjusted 
SLEDAI-2K values in our analyses were usually based on yearly assessments, and thus we may have 
missed some relevant information on disease activity. In addition, anti-DNA antibodies were measured 
by different standard techniques at different centres and/or across the course of the study. Enzyme-
linked immunosorbent assays were used most frequently, followed by Crithidia and rarely Farr 
radioimmunoassay. Anti-dsDNA antibody results may be variable between assays. Moreover, the 
dsDNA antibody test information that we relied on recorded results as positive or negative; thus, we 
could not assess the effect of antibody titre on breast cancer risk. As well, we did not have information 
on past mammography screening or estrogen receptor status on the cases. 
 Potentially most importantly, the strongest current hypothesis concerning the role of anti-dsDNA 
antibodies in mediating cancer risk in SLE is that the effect may be due only to specific subtypes of 
antibodies, that is, cell-penetrating autoantibodies, which may represent only a subset of the anti-DNA 
antibodies found in SLE. This may also explain the lack of an association between anti-DNA antibodies 
and lowered breast cancer risk. Finally, we did not attempt to assess whether different subtypes of breast 
cancer are affected preferentially by anti-ds DNA antibodies, or whether the antibodies affected the 
course of breast cancer. These are all areas of potential interest for future study. 
We also did not find a clear association between breast cancer and lupus-related drug exposure. 
Cyclophosphamide has been suspected of being a trigger for certain malignancies in diseases like SLE, 
6 
 
particularly hematological cancers [9] though it has not been clearly linked to breast cancers. On the 
other hand antimalarial drugs (commonly used in SLE) have been proposed to have a potential role in 
lowering cancer risk15.[15] One hypothesis is that anti-malarial drugs might promote, in cancer cells, a 
type of cell death process called autophagy.16, 17.[16-17] Our current analyses do not strongly suggest a 
protective role for this agent, at least with respect to breast cancer. However, even with our large 
sample, most of the drug effect estimates were too imprecise to definitively rule out positive or negative 
effects on breast cancer risk in SLE.   
As might be expected (being risk factors for breast cancer in the general population18[18]), age 
was an important risk factor for breast cancer, in unadjusted and adjusted analyses. White race, 
menopausal status, ever-use of hormone replacement therapy, and family history of breast cancer were 
associated with breast cancer in univariate analyses, although the associations were less clear in the 
multivariate analyses.  Within the general population, women of different racial/ethnic groups have 
different breast cancer risk profiles. This likely explains the higher breast cancer rates for white SLE 
patients in our univariate analysis. 
Earlier, we used general population breast cancer genome-wide association study (GWAS) data, 
to explore whether single nucleotide polymorphisms (SNPs) predisposing to SLE might be protective 
against breast cancer (in women in the general population)19( [19]. We focused on loci relevant to 10 SNPs 
that are highly associated with SLE. The one SLE-related SNP with a potentially protective odds ratio 
(OR) within the GWAS breast cancer cases versus controls, was the rs9888739-C allele (OR 0.90755, 
uncorrected p value 0.0499, which is not strongly convincing). Thus if a decreased breast cancer risk in 
SLE is influenced by genetic profiles, this may be due to other SNPs, complex interactions, and/or 
epigenetic factors. 
In summary, in our study of over 4,000 SLE patients, the principal factors associated with breast 
cancers were older age at cohort entry. There was little evidence that breast cancer risk in this SLE 
sample was strongly driven by any of the clinical factors that we studied. Further search for factors that 
determine the lower risk of breast cancer in SLE is warranted. 
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